Oncology

26 drugs are in development for Ovarian Cancer.

BioSniper AIPage evidence connected

Prepared research question

Which programs lead the Ovarian Cancer pipeline—and what evidence could change the picture?

Traceable citations · Unknowns marked

Drug Pipeline by Phase

Phase 3(3)

Phase 2(3)

Drug	Company
kevetrin	Innovation Pharmaceuticals Inc. (IPIX)
ngm120	NGM BIOPHARMACEUTICALS INC (NGM)
STRO-002	SUTRO BIOPHARMA, INC. (STRO)

Phase 1(14)

Drug	Company
CUE-102	Cue Biopharma, Inc. (CUE)
hwk-007	Whitehawk Therapeutics, Inc. (WHWK)
lncb74	NextCure, Inc. (NXTC)
NUV-868	Nuvation Bio Inc. (NUVB)
nxp800	Nuvectis Pharma, Inc. (NVCT)
prolanta	ONCOLIX, INC. (AEPP)
tsc-200-a0201	TScan Therapeutics, Inc. (TCRX)
tsc-201-b0702	TScan Therapeutics, Inc. (TCRX)
tsc-202-a0201	TScan Therapeutics, Inc. (TCRX)
tsc-203-a0201	TScan Therapeutics, Inc. (TCRX)
tsc-204-a0201	TScan Therapeutics, Inc. (TCRX)
tsc-204-c0702	TScan Therapeutics, Inc. (TCRX)
XmAb808	Xencor Inc (XNCR)
xmt-1660	Mersana Therapeutics, Inc. (MRSN)

Phase 1/Phase 2(6)

Drug	Company
eli-002 2p	Elicio Therapeutics, Inc. (ELTX)
FT836	FATE THERAPEUTICS INC (FATE)
gavo-cel	TCR2 THERAPEUTICS INC. (TCRR)
nc410	NextCure, Inc. (NXTC)
tc-510	TCR2 THERAPEUTICS INC. (TCRR)
XmAb541	Xencor Inc (XNCR)

About this indication

Oncology·MeSH: Ovarian Neoplasms (D010051)

Narrower concept of MeSH descriptor Ovarian Neoplasms

Prevalence

24.0 / 100K

Incidence

10.6 / 100K/yr

BioSniper tracks 26 drugs in development for Ovarian Cancer across 17 companies.

There are 185 clinical trials targeting Ovarian Cancer tracked by BioSniper.

The estimated prevalence of Ovarian Cancer is approximately 24.0 per 100,000 population.